EA201790236A1 - Антитела против vasa и способы их получения и использования - Google Patents

Антитела против vasa и способы их получения и использования

Info

Publication number
EA201790236A1
EA201790236A1 EA201790236A EA201790236A EA201790236A1 EA 201790236 A1 EA201790236 A1 EA 201790236A1 EA 201790236 A EA201790236 A EA 201790236A EA 201790236 A EA201790236 A EA 201790236A EA 201790236 A1 EA201790236 A1 EA 201790236A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vasa
mabs
methods
production
disclosed
Prior art date
Application number
EA201790236A
Other languages
English (en)
Inventor
Дэвид Т. Уивер
Бо Чжан
Original Assignee
Оувэсайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оувэсайенс, Инк. filed Critical Оувэсайенс, Инк.
Publication of EA201790236A1 publication Critical patent/EA201790236A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Abstract

Раскрыты антитела (mAb) против VASA, в частности гуманизированные mAb, которые специфично связываются с VASA с высокой аффинностью. Предоставлены аминокислотные последовательности CDR легких цепей и тяжелых цепей, а также консенсусные последовательности для этих CDR этих mAb против VASA. Также раскрытие предусматривает молекулы нуклеиновой кислоты, которые кодируют mAb против VASA, экспрессирующие векторы, клетки-хозяева, способы получения mAb против VASA и способы экспрессии mAb против VASA. Наконец, раскрыты способы использования mAb против VASA для того, чтобы выделять и/или очищать клетки, экспрессирующие VASA.
EA201790236A 2014-09-16 2015-09-16 Антитела против vasa и способы их получения и использования EA201790236A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
EA201790236A1 true EA201790236A1 (ru) 2017-11-30

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790236A EA201790236A1 (ru) 2014-09-16 2015-09-16 Антитела против vasa и способы их получения и использования

Country Status (26)

Country Link
US (4) US9403913B2 (ru)
EP (1) EP3194448A4 (ru)
JP (2) JP2017532953A (ru)
KR (1) KR20170056521A (ru)
CN (1) CN106573985A (ru)
AP (1) AP2017009758A0 (ru)
AU (1) AU2015317813B2 (ru)
BR (1) BR112017003263A2 (ru)
CA (1) CA2959179A1 (ru)
CL (1) CL2017000402A1 (ru)
CO (1) CO2017001724A2 (ru)
CR (1) CR20170067A (ru)
DO (1) DOP2017000050A (ru)
EA (1) EA201790236A1 (ru)
EC (1) ECSP17011262A (ru)
GT (1) GT201700036A (ru)
IL (1) IL250451A0 (ru)
MX (1) MX358243B (ru)
NI (1) NI201700022A (ru)
PE (1) PE20170667A1 (ru)
PH (1) PH12017500309A1 (ru)
SG (1) SG11201701016WA (ru)
SV (1) SV2017005393A (ru)
TN (1) TN2017000066A1 (ru)
TW (1) TW201619194A (ru)
WO (1) WO2016044436A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
WO2021096829A1 (en) * 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
WO2001036445A1 (en) 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
WO2006001938A2 (en) 2004-05-17 2006-01-05 The General Hospital Corporation Methods and compositions for producing germ cells from bone marrow derived germline stem cells
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
PL1674111T3 (pl) * 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
WO2010035465A1 (ja) 2008-09-25 2010-04-01 国立大学法人東京海洋大学 抗マグロＶａｓａ抗体
SG172427A1 (en) * 2008-12-26 2011-07-28 Univ Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
EP2462161B1 (en) * 2009-08-06 2017-03-08 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
NZ706806A (en) 2011-04-14 2016-12-23 Gen Hospital Corp Compositions and methods for autologous germline mitochondrial energy transfer
BR112013033797A2 (pt) * 2011-06-29 2017-02-14 Harvard College composição, célula isolada, mitocôndria isolada , métodos de preparo de um oócito, de fertilização in vitro, de melhora de fertilidade em um indivíduo, de sustentação de desenvolvimento embrionário, de recuperação ou aumento de função ovariana em um indivíduo, de preparo de um tecido ou célula do mesmo, e de produção de um oócito, oócito, e, agente bioenergético
WO2014106235A1 (en) * 2012-12-31 2014-07-03 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
WO2016115077A1 (en) * 2015-01-13 2016-07-21 President And Fellows Of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
MX2017002390A (es) 2017-07-28
TW201619194A (zh) 2016-06-01
BR112017003263A2 (pt) 2017-11-28
US9403913B2 (en) 2016-08-02
DOP2017000050A (es) 2018-04-15
JP2017532953A (ja) 2017-11-09
CN106573985A (zh) 2017-04-19
MX358243B (es) 2018-08-10
NI201700022A (es) 2017-05-04
SV2017005393A (es) 2017-06-07
PE20170667A1 (es) 2017-06-06
AU2015317813B2 (en) 2018-04-05
AU2015317813A1 (en) 2017-03-02
KR20170056521A (ko) 2017-05-23
CR20170067A (es) 2017-05-10
TN2017000066A1 (en) 2018-07-04
US20160075797A1 (en) 2016-03-17
CA2959179A1 (en) 2016-03-24
JP2018148915A (ja) 2018-09-27
US20160311929A1 (en) 2016-10-27
AP2017009758A0 (en) 2017-02-28
US20170107299A1 (en) 2017-04-20
US20180155445A1 (en) 2018-06-07
EP3194448A4 (en) 2018-03-14
CL2017000402A1 (es) 2017-11-03
PH12017500309A1 (en) 2017-07-10
US9567404B2 (en) 2017-02-14
WO2016044436A2 (en) 2016-03-24
WO2016044436A3 (en) 2016-06-09
GT201700036A (es) 2018-12-19
EP3194448A2 (en) 2017-07-26
CO2017001724A2 (es) 2017-07-19
SG11201701016WA (en) 2017-03-30
IL250451A0 (en) 2017-03-30
ECSP17011262A (es) 2017-05-31

Similar Documents

Publication Publication Date Title
EA201790236A1 (ru) Антитела против vasa и способы их получения и использования
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR106365A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201790307A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2016016883A (es) Anticuerpo anti-axl.
DOP2014000007A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201692495A8 (ru) Биспецифические антитела к il4-il13
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
AR101891A1 (es) Anticuerpos anti-vasa, y métodos de producción y uso de los mismos